Table 5 Univariate and multivariate analysis of factors associated with overall survival and progression free survival (n = 49)

Age

2.615(0.693 ~ 9.865)

0.156

3.274(1.069 ~ 10.030)

0.038

1.149(0.111 ~ 11.872)

0.907

0.736

ASA (I + II vs. III + IV)

0.204(0.025 ~ 1.668)

0.138

0.411(0.113 ~ 1.504)

0.179

CA125

33.280(0.040 ~ 27,705.853)

0.307

25.129(0.008 ~ 79,761.009)

0.433

CA19–9

9.707(1.134 ~ 83.096)

0.038

19.599(1.441 ~ 266.656)

0.025

0.104

3.930(0.933 ~ 16.554)

0.062

6.122(0.737 ~ 50.873)

0.094

0.052

HE4

64.472(0.089 ~ 46,669.453)

0.215

5.014(0.959 ~ 26.217)

0.056

9.898(0.962 ~ 101.809)

0.054

0.027

FIGO stage (IA ~ IIIB vs. IIIC~IV)

12.800(2.654 ~ 61.724)

0.001

1.637(0.145 ~ 18.447)

0.690

0.338

5.835(1.909 ~ 17.838)

0.002

1.369(0.130 ~ 14.396)

0.794

0.331

Ascites (≥2000 ml)

8.150(1.508 ~ 44.054)

0.015

20.924(0.940 ~ 465.542)

0.055

0.001

3.746(0.787 ~ 17.841)

0.097

18.498(0.964 ~ 354.767)

0.053

0.001

Lymphadenectomy

0.459(0.115 ~ 1.837)

0.271

0.448(0.137 ~ 1.466)

0.184

Comorbid illnesses

0.755(0.188 ~ 3.026)

0.691

0.893(0.292 ~ 2.730)

0.842

Multiple comorbid illnesses

1.263(0.155 ~ 10.301)

0.827

0.679(0.088 ~ 5.228)

0.710

Thrombosis

0.042(0.000 ~ 911.409)

0.533

0.044(0.000 ~ 329.984)

0.492

Endometriosis

0.549(0.069 ~ 4.402)

0.573

0.340(0.044 ~ 2.619)

0.300

Interval ^b (> 14 days)

0.419(0.104 ~ 1.686)

0.221

0.440(0.143 ~ 1.349)

0.151

Suboptimal cytoreduction

4.112(0.821 ~ 20.583)

0.085

1.026(0.064 ~ 16.408)

0.986

0.715

3.116(0.687 ~ 14.130)

0.141

SCS (< 4 vs. ≥4)

0.523(0.140 ~ 1.959)

0.336

0.725(0.237 ~ 2.218)

0.573